콘텐츠로 건너뛰기
Merck

Sustaining Rapid Medicine Development

Lessons From A Pandemic


The Economist Impact Report: Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape

Can drug developers and regulators create a sustainable culture that allows the biopharma industry to continue to work with the accelerated model adopted during the COVID-19 pandemic, or will industry burnout ensue?  

Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape

This report examines the following questions:

  • What will the biopharma regulatory science landscape look like in 2027?
  • What role will governments, regulators, and investors play in boosting the ecosystem for biopharma innovation, including sustainability targets?
  • Which therapeutic areas and technologies lend themselves to biopharma industry collaboration?
  • What will accelerate innovation cycles and regulatory approvals post-pandemic?
  • How will regulators deal with digitalization, artificial intelligence and machine learning in the drug approval process?

The art of the possible: reimagining the biopharmaceutical supply chain

October 4th, 2022 10 am EDT/ 3pm BST

Meeta Gulyani Head of Strategy, Business Development and Sustainability, Life Science MilliporeSigma

Meeta Gulyani

Meeta Gulyani Head of Strategy, Business Development and Sustainability, Life Science MilliporeSigma

Mike Douma Vice President, Supply Chain AbbVie

Mike Douma

Vice President, Supply Chain AbbVie

Tacy Foster Partner McKinsey

Tacy Foster

Partner, McKinsey

Anne McDonald Pritchett Senior Vice President, Policy and Research PhRMA

Anne McDonald Pritchett

Senior Vice President, Policy and Research PhRMA

Alan Lovell Senior Manager, Health, Policy and Insights Economist Impact

Alan Lovell

Senior Manager, Health, Policy and Insights Economist Impact

Programmed by Economist Impact and sponsored by Merck, The art of the possible: reimagining the biopharmaceutical supply chain will examine what leaders in the biopharmaceutical supply chain must do to steer their businesses through a time of rapid change and ongoing disruption, and identify synergies and efficiencies to bring drugs to market more effectively.


계속하려면 로그인하세요.

계속 읽으시려면 로그인하거나 계정을 생성하세요.

계정이 없으십니까?